adesso (ADN1) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
8 Jul, 2026Executive summary
Sales increased 16% year-over-year to €631.1 million in H1 2024, driven almost entirely by organic growth, with all industries and regions contributing positively.
EBITDA rose 10% to €27.7 million, but consolidated earnings were negative at -€9.9 million, with EPS at -€1.51, reflecting margin pressure and higher costs.
The IT services segment performed well, while the IT solutions segment underperformed due to weak license sales and ongoing investments.
International expansion continued, including acquisitions in Sweden, Romania, Italy, India, Saudi Arabia, and Turkey, with employee headcount outside Germany up 12% year-over-year.
The company maintains a profitable growth strategy, aiming to grow at least twice the market rate and to continuously increase dividends.
Financial highlights
Revenue reached €631.1 million, up 16% year-over-year, with Germany growing 17% and DACH region accounting for 95% of volume.
EBITDA increased to €27.7 million (+10%), but EBITDA margin fell to 4.4% (down from 4.6%).
Consolidated earnings for H1 2024 were negative at -€9.9 million; EPS was -€1.51.
Net debt improved to -€115.4 million from -€143.4 million year-over-year; net working capital decreased by 17%.
Free cash flow improved year-over-year, reaching record levels, supported by factoring.
Outlook and guidance
Full-year 2024 sales guidance of above €1.25 billion reaffirmed; EBITDA guidance lowered to €80–110 million from €110–130 million.
H2 earnings expected to be stronger due to improved utilization and five additional working days.
IT solutions segment expected to remain weak in 2024, with recovery anticipated in H2 2025.
Hiring pace reduced, but investments in talent and product development continue.
Opportunities for higher license sales in H2, especially in IT Solutions.
Latest events from adesso
- Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU9 Jul 2026 - Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 20258 Jul 2026 - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 20248 Jul 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025